Mechanistic Insights Into OSM and IL ‐31 in Primary Localized Cutaneous Amyloidosis: A Narrative Review
International Journal of Dermatology · 2026-08 · 65 (8) · 1611-1624
DOI: 10.1111/ijd.70436 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Dermatology, online erschienen am 24.04.2026. Verfasst von Yi Teng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Interleukins, Oncostatin M, Amyloidosis, Familial, Skin Diseases, Genetic. Die Arbeit nennt 106 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Sichuan Province.
Abstract (Originalsprache)
Primary localized cutaneous amyloidosis (PLCA) is a chronic pruritic dermatological disorder characterized by amyloid deposits in the papillary dermis, significantly impairing patients' quality of life. Although the pathogenesis of PLCA is multifaceted, emerging evidence highlights the pivotal role of dysregulated cytokines, particularly the members of interleukin‐6 (IL‐6) cytokines family in PLCA. Oncostatin M (OSM) mediates keratinocyte proliferation through the STAT5‐KLF7 axis upon OSMRβ engagement. Pathogenic variants in OSMR disrupt receptor dimerization, thereby suppressing signal transduction. These alterations together with cytokine dysregulation concomitantly elevate the expression of AHNAK and suppress that of Bcl‐xL, which accelerate keratinocyte differentiation and apoptosis respectively, leading to the thickening of the stratum corneum and amyloid fibril deposition. Furthermore, dysregulated expression of chemokine monocyte chemoattractant protein‐1 (MCP‐1) by pathogenic variant in IL‐31RA reduces monocyte‐mediated clearance of amyloid fibrils, thereby promoting their pathological retention. The mechanisms of IL‐31‐mediated pruritus remain to be elucidated, given the conflicting observations that while some studies report wider cutaneous innervation in FPLCA patients, others demonstrate opposing results in general lichen amyloidosis patients. This review aims to synthesize recent advances in understanding PLCA pathogenesis with a focus on IL‐31 and OSM cytokines network dysregulation especially driven by pathogenic variants, and provide critical insights for identifying therapeutic targets and put forward challenges in the future. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- West China School of Medicine, Sichuan University, Chengdu, Sichuan, China.
- Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, Chi…
- Department of Dermatology & Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
ORCID-Profile: Kaixin Lei, Wei Li
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Sichuan Province
Zitieren
APA
Teng, Y., Zhou, X., Xiao, Y., Lei, K., Dai, L., & Li, W. (2026). Mechanistic Insights Into OSM and IL ‐31 in Primary Localized Cutaneous Amyloidosis: A Narrative Review. International Journal of Dermatology, 65(8), 1611-1624. https://doi.org/10.1111/ijd.70436
Vancouver
Teng Y, Zhou X, Xiao Y, Lei K, Dai L, Li W. Mechanistic Insights Into OSM and IL ‐31 in Primary Localized Cutaneous Amyloidosis: A Narrative Review. International Journal of Dermatology. 2026;65(8):1611-1624. doi:10.1111/ijd.70436
BibTeX
@article{Teng2026,
author = {Teng, Yi and Zhou, Xingli and Xiao, Yue and Lei, Kaixin and Dai, Lunzhi and Li, Wei},
title = {Mechanistic Insights Into OSM and IL ‐31 in Primary Localized Cutaneous Amyloidosis: A Narrative Review},
journal = {International Journal of Dermatology},
year = {2026},
volume = {65},
number = {8},
pages = {1611--1624},
doi = {10.1111/ijd.70436}
}
EUVIMED